32 results about "Nisoldipine" patented technology

Controlled release oral dosage formulations containing calcium channel blockers, and methods of use thereof, are provided for the once-a-day treatment of cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmia. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. The formulation provides an increase in the bioavailability of the calcium channel blocker as compared to the bioavailability of the calcium channel blocker in other drug delivery formulations known in the art. In one embodiment, the formulation provides an increase in the bioavailability of the calcium channel blocker, nisoldipine, as compared to the same dose of nisoldipine in the coat-core version of the drug (SULAR®). The formulation can be in the form of a trilayer tablet containing a core or central layer and one or more barrier layers.

Controlled release oral dosage formulations containing calcium channel blockers, and methods of use thereof, are provided for the once-a-day treatment of cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmia. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. The formulation provides an increase in the bioavailability of the calcium channel blocker as compared to the bioavailability of the calcium channel blocker in other drug delivery formulations known in the art. In one embodiment, the formulation provides an increase in the bioavailability of the calcium channel blocker, nisoldipine, as compared to the same dose of nisoldipine in the coat-core version of the drug (SULAR®). The formulation can be in the form of a trilayer tablet containing a core or central layer and one or more barrier layers.

The invention belongs to the field of sustained-release drugs, particularly relates to a nisoldipine sustained-release dropping pill and the preparation method thereof, and aims to supplement the deficiency of the prior art and provide a sustained-release nisoldipine dropping pill formulation. The sustained-release nisoldipine dropping pill is prepared by adding stabilize Vitamin E and hydrophobic framework ingredients to guarantee no occurrence of an obvious change related to the substance content for the drug during the effective storage period and has the advantages of full release, controllable release time and high bioavailability simultaneously. The sustained-release nisoldipine dropping pill is suitable for clinical and family use.

A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine, anipamil, barnidipine, benidipine, bepridil, darodipine, diltiazem, efonidipine, felodipine, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, mepirodipine, nicardipine, nifedipine, niludipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, perhexiline, tiapamil, verapamil and pharmaceutically acceptable salts thereof, are suitable calcium channel blockers.

The invention belongs to the field of pharmaceutic preparation, and particularly relates to a transdermal patch of antihypertensive drug nisoldipine, and a preparation method thereof. The nisoldipine controlled-release patch disclosed by the invention is composed of a backing layer, a drug-polymer layer and a release liner, wherein the drug-polymer layer is composed of drug nisoldipine, a drug-polymer, a penetration enhancer and a plasticizer. The nisoldipine transdermal patch prepared by the preparation method can lastingly release drug within three days at a constant speed.

Controlled release oral dosage formulations containing calcium channel blocker and processes for preparation thereof, are provided for once a day treatment. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. In one embodiment, the formulation provides controlled release of micronized nisoldipine with one or more pH independent release controlling polymers. The controlled release matrix formulation is advantageous and can be prepared by a simple, economically viable process as compared to complex core-coat prior-art versions.

The invention discloses a double-cable composited damping cable which comprises a main cable, an auxiliary cable, a first support, a second support and a viscous damper. The first support and the second support are installed on the ground, one end of the main cable is connected with a bridge main beam, the other end of the main cable is connected with one end of the viscous damper, the other end of the viscous damper is connected with the first support, the auxiliary cable is located above the main cable, two ends of the auxiliary cable are respectively connected to the bridge main beam and the second support, and the main cable and the auxiliary cable are connected through multiple vertical booms. The main cable and the auxiliary cable are combined, so that the sag of the main cable is basically eliminated, the longitudinal (axial) rigidity of the main cable is large due to small sag when larger-amplitude structural vibration is produced, and the cable force change is remarkable. Due to the fact the auxiliary cable is large in sag, the longitudinal rigidity of the auxiliary cable is small, the cable force change is very small, and conditions are provided for energy consumption on horizontally and remotely installed damper.

The invention discloses a high purity nisoldipine compound, which comprises the following steps: (1) dissolving a certain amount of rough nisoldipine products in an organic solvent, adding activated carbon into the organic solvent to absorb and filter, collecting filtrate, and reducing pressure and concentrating to obtain primary purified nisoldipine; (2) separating and purifying the primary purified nisoldipine by using a preparation type chromatographic column, and collecting eluent to obtain secondary purified nisoldipine; and (3) decompressing and concentrating the eluent, adding water while stirring, performing heating and backflow, performing cooling and crystallization, and centrifugally washing and drying precipitated crystals to obtain tertiary purified nisoldipine. By means of the method, the nisoldipine produced has high purity, the toxic and side effects of prepared pharmaceuticals for treating hemorrhagic cerebrovascular diseases, high blood pressure and the like are reduced, product quality of preparation is improved, and the high purity nisoldipine compound is suitable for large-scale industrialization production.

The invention discloses a preparation method of nisoldipine impurity. The nisoldipine impurity is 2,6-dimethyl-4-(2-nitrosophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate methyl isobutyl ester, the structure is as follows: Ⅰ) as shown. The preparation method of the nisoldipine impurity is prepared by taking nisoldipine as a raw material, adding a free radical initiator, and undergoing one-step photodegradation. The method adopted in the present invention is simple, easy to operate, mild in reaction conditions, and simple in post-treatment process, and provides a new way for further identifying, separating, preparing and characterizing the nisoldipine impurities, improving the quality control level and medication safety of nisoldipine, It is beneficial to the control of the quality of medicines in the production process.

Synthetic process of isobutyl methyl 1,4,-dihydro-2,6-dimethyl-4-(2-nitrophenyl)3,5-pyridine dicarboxylate (Nisoldipine) comprising on the reaction of isobutyl 2-(2-nitrobenzylidene)acetoacetate with methyl 3-aminocrotonate in an apolar solvent.